AZD4831 for NASH with Fibrosis (COSMOS Trial)

"Clinicaltrials.gov lists this research trial as actively recruiting, having originally gone live on October 26th 2022 and most recently modified on November 25th 2022."

"The safety profile of AZD4831 has been assessed at a 2, as the current trial is in its second phase and there is data to back up claims about its security but none confirming efficacy."

"The requirements for entry into this medical trial necessitates that participants are aged between 18 and 75. Separately, there exist 98 trials targeting those under the legal age of consent and 543 studies geared towards people over retirement age."

"Affirmative. Evidence hosted on clinicaltrials.gov affirms that this medical research is in the midst of looking for candidates, having first been posted on October 26th 2022 and most recently updated November 25th 2022. The study requires 90 participants to be recruited from 9 different sites."

"Currently, 9 medical sites are recruiting patients to partake in this study. These locations span from Stanford and Miami all the way down to Tucson. To minimize travelling needs should you decide to enroll, it is best that you choose a site nearest your home area."

"This study is enrolling 90 individuals aged 18-75 with non-cirrhotic, non-alcoholic steatohepatitis and fibrosis. All applicants must have maintained a stable weight for the last three months prior to screening (defined as 5% or less change), display NAS scores of 4+ with components like steatosis, lobular inflammation, and ballooning all registering at 1+, an ALT reading above the upper limit but below 300 U/L during screening, and either be male of non-childbearing potential or female using contraceptives in accordance with local regulations."